Incretin mimetics and incretin enhancers for the treatment of type 2 diabetes;Les incrétinomimétiques et incrétinopotentiateurs dans le traitement du diabète de type 2

Revue Medicale Suisse

Volumn 3, Issue 122, 2007, Pages 1884-1888

  Scheen, André J ^a   Radermecker, Régis P ^a   Philips, Jean Christophe ^a   Paquot, Nicolas ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; INCRETIN; INSULIN DETEMIR; LIRAGLUTIDE; METFORMIN; SAXAGLIPTIN; SITAGLIPTIN; VILDAGLIPTIN;

ARTICLE; BLOOD GLUCOSE MONITORING; BODY WEIGHT; DRUG MECHANISM; ENZYME DEGRADATION; FOOD INTAKE; GLUCAGON RELEASE; HUMAN; HYPOGLYCEMIA; INSULIN RELEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; STOMACH EMPTYING;

ANTIGENS, CD26; DIABETES MELLITUS, TYPE 2; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS;

EID: 34548778650     PISSN: 16609379     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Scheen AJ. Pathophysiology of insulin secretion. Ann Endocrinol (Paris) 2004;65:29-36.
2. * Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes: Principles of pathogenesis and therapy. Lancet 2005;365:1333-46.
3. * Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006;29:1963-72 and Diabetologia 2006;49:1711-21.
4. Rendell M. The role of sulphonyl ureas in the management of type 2 diabetes mellitus. Drugs 2004;64:1339-58.
5. Dornhorst A. Insulinotropic meglitinide analogues. Lancet 2001;358:1709-16.
6. Krentz AJ, Bailey CJ. Oral antidiabetic agents. Current role in type 2 diabetes mellitus. Drugs 2005;65:385-411.
7. Gautier JF, Fetita S, Sobngwi E, Salaun-Martin C. Biological actions of the incretins GIP and GLP-1 and therapeutic perspectives in patients with type 2 diabetes. Diabetes Metab 2005;31:233-42.
8. ** Drucker DJ, Nauck MA. The incretin system: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006;368:1696-705.
9. Scheen AJ. Le glucagon-like peptide-1 (GLP-1), nouvelle cible dans le traitement du diabete de type 2. Rev Med Liège 2007;62:216-9.
10. Keating GM. Exenatide. Drugs 2005;65:1681-92.
11. DeFronzo RA, Ratner RE, Han J, et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005;28:1092-100.
12. Heine RJ, Van Gaal LF, Johns D, et al. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: A randomized trial. Ann Intern Med 2005;143:559-69.
13. Vilsbell T. Liraglutide :A once-daily GLP-1 analogue for the treatment of Type 2 diabetes mellitus. Expert Opin Invest Drugs 2007;16:231-7.
14. * Idris S, Donnelly R. Dipeptidyl peptidase-IV inhibitors: A major new class of oral antidiabetic drug. Diab Obes Metab 2007;9:153-65.
15. Lyseng-Williamson KA. Sitagliptin. Drugs 2007;67:587-97.
16. Henness S, Keam SJ. Vildagliptin. Drugs 2006;66:1989-2001.
17. Charbonnel B, Karasik A, Liu J, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 2006;29:2638-43.
18. Nauck M, Meiniger G, Sheng D, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone:A randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 2007;9:194-205.